Loading clinical trials...
Loading clinical trials...
A study to evaluate the efficacy and safety of maralixibat in infants with Biliary Atresia (BA) after Hepatoportoenterostomy (HPE, also known as the Kasai procedure).
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Mirum Pharmaceuticals, Inc.
NCT05848310 · Biliary Atresia, Prognosis
NCT06764082 · Nutrition Disorder, Infant, Biliary Atresia
NCT00345553 · Biliary Atresia
NCT05072626 · Biliary Atresia, Infant, and more
NCT02137668 · Primary Sclerosing Cholangitis, Biliary Atresia
Phoenix Children's Division of Gastroenterology & Hepatology
Phoenix, Arizona
Children's Healthcare of Atlanta - Emory University School of Medicine
Atlanta, Georgia
NYU Grossman School of Medicine
New York, New York
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions